Qiagen
QIAGEN N.V. is a Netherlands-based provider of sample preparation and assay technologies for molecular diagnostics, applied testing, and academic research. The company supplies integrated workflows that enable customers to extract and analyze DNA, RNA, and proteins from biological samples. Its principal products encompass proprietary reagent kits, automated laboratory instrumentation, and bioinformatics software utilized in clinical testing and drug discovery. Revenue is driven primarily through consumable-based sales of reagent kits alongside instrument placements to molecular laboratories. The primary end markets comprise clinical healthcare laboratories, pharmaceutical research organizations, and academic institutions worldwide. As an established participant in molecular biology and testing, the enterprise plays a key role in diagnostic solutions. Headquartered in Venlo, Netherlands, QIAGEN N.V. is publicly listed on the Frankfurt Stock Exchange and the New York Stock Exchange.
38 of the funds FundTelligence covers report a position in Qiagen.
- Legal name
- QIAGEN
- Sector
- Health Care
- Country
- Netherlands
- Funds holding it
- 38
- Exposure themes
- Genomics & Profiling, Genomic Tools, Precision Medicine & Genomics
Funds holding Qiagen
- Schroder ISF European Equity Impact — Schroders · 2.95 % (full portfolio disclosed, December 2025)
- Nordea European Small and Mid Cap Sustainable Stars — Nordea Funds · 2.27 % (full portfolio disclosed, July 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 1.02 % (full portfolio disclosed, October 2026)
- DNB Health Care — DNB · 0.7 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI World Health Care Sector ESG UCITS ETF — BlackRock · 0.57 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI Europe Health Care Sector UCITS ETF — BlackRock · 0.53 % (full portfolio disclosed, October 2026)
- DNB Fund Low Volatility Equities — DNB · 0.18 % (full portfolio disclosed, September 2026)
- Danske Invest Europe Index Restricted — Danske Invest · 0.12 % (full portfolio disclosed, July 2026)
Showing the 8 largest of 38 funds holding it.